NZ 602934 The disclosure relates to a matrix controlled-release pharmaceutical formulation comprising desvenlafaxine succinate, having a mean mass diameter (MMD) of between about 5&mum and about 100&mum and at least one matrix rate-controlling pharmaceutically acceptable polymer selected from the group consisting of polyvinyl acetate (PVA) and polyvinylpyrollidone (PVP) copolymer, polyvinylpyrollidone, methacrylic/methacrylate polymers and copolymers, celluloses such as ethylcellulose and hydroxypropyl methylcellulose, and polyethylene oxide polymers. Also disclosed is a method for the preparation of said formulation and use thereof in the treatment of depression and related central nervous system disorders and diseases.
